CA3146477A1 - Use of sepiapterin and metabolites thereof to treat radiation exposure - Google Patents

Use of sepiapterin and metabolites thereof to treat radiation exposure Download PDF

Info

Publication number
CA3146477A1
CA3146477A1 CA3146477A CA3146477A CA3146477A1 CA 3146477 A1 CA3146477 A1 CA 3146477A1 CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A1 CA3146477 A1 CA 3146477A1
Authority
CA
Canada
Prior art keywords
mir
subject
radiation
administering
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146477A
Other languages
English (en)
French (fr)
Inventor
Eleonora MEZZAROMA
Christopher RABENDER
Ross MIKKELSEN
Vasily YAKOVLEV
Neil Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
PTC Therapeutics MP Inc
Original Assignee
Virginia Commonwealth University
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, PTC Therapeutics MP Inc filed Critical Virginia Commonwealth University
Publication of CA3146477A1 publication Critical patent/CA3146477A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3146477A 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure Pending CA3146477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882,937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
CA3146477A1 true CA3146477A1 (en) 2021-02-11

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146477A Pending CA3146477A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN114555090B (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
MX379061B (es) 2013-09-13 2025-03-04 Bioventures Llc Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
CN106794197A (zh) 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
CN114555090A (zh) 2022-05-27
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
FI4009978T3 (fi) 2024-11-01
JP2025098011A (ja) 2025-07-01
EP4009978A1 (en) 2022-06-15
HUE069012T2 (hu) 2025-02-28
EP4009978B1 (en) 2024-09-25
ES2994060T3 (en) 2025-01-16
CN119837879A (zh) 2025-04-18
SI4009978T1 (sl) 2025-03-31
BR112022002029A2 (pt) 2022-06-07
RS66096B1 (sr) 2024-11-29
AU2020324435A1 (en) 2022-02-24
JP2022543655A (ja) 2022-10-13
IL290321B1 (en) 2026-04-01
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
PT4009978T (pt) 2024-11-05
WO2021026247A1 (en) 2021-02-11
IL290321A (en) 2022-04-01
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10
MX2022001535A (es) 2022-03-04
AU2020324435B2 (en) 2026-03-19
DK4009978T3 (da) 2024-10-14
SMT202500089T1 (it) 2025-03-12
EP4454712A2 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
AU2020324435B2 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
Wang et al. The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest
JP2018507244A (ja) 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
US20090318534A1 (en) Methods and compositions for the treatment of skin diseases and disorders
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
WO2022053019A1 (en) Methods for treating metastasis with cathepsin c inhibitors
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2019510743A (ja) 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート（ｄｍｆ）
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
CN101432000B (zh) 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂
EP4545076A1 (en) Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure
WO1998051313A1 (fr) Remedes contre les yeux secs
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
WO2022195579A1 (en) Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250723